Artivion (NYSE:AORT) SVP Andrew Green Sells 6,510 Shares of Stock

Artivion, Inc. (NYSE:AORT) SVP Andrew Green sold 6,510 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $27.27, for a total value of $177,527.70. Following the completion of the sale, the senior vice president directly owned 53,133 shares of the company’s stock, valued at $1,448,936.91. This represents a 10.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Artivion Price Performance

Artivion stock traded down $0.01 during midday trading on Friday, reaching $25.61. The company’s stock had a trading volume of 139,212 shares, compared to its average volume of 597,321. The firm has a market capitalization of $1.25 billion, a PE ratio of -365.49 and a beta of 1.25. Artivion, Inc. has a fifty-two week low of $19.16 and a fifty-two week high of $48.25. The stock’s 50 day simple moving average is $26.05 and its 200 day simple moving average is $29.23. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. The business had revenue of $125.76 million for the quarter, compared to analysts’ expectations of $119.99 million. On average, equities research analysts forecast that Artivion, Inc. will post 0.45 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently weighed in on AORT. Citigroup reaffirmed a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Weiss Ratings cut Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Citizens Jmp cut their price target on Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a research note on Friday, May 8th. Stifel Nicolaus set a $45.00 price objective on shares of Artivion in a research report on Monday, June 1st. Finally, Wall Street Zen lowered shares of Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Artivion presently has an average rating of “Moderate Buy” and an average price target of $44.83.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in AORT. Corient Private Wealth LP purchased a new position in Artivion in the 2nd quarter valued at about $3,581,000. California State Teachers Retirement System grew its stake in Artivion by 2,086.7% in the 2nd quarter. California State Teachers Retirement System now owns 1,119,860 shares of the company’s stock worth $25,163,000 after acquiring an additional 1,068,647 shares during the period. Susquehanna International Group LLP raised its holdings in Artivion by 584.1% in the 2nd quarter. Susquehanna International Group LLP now owns 102,531 shares of the company’s stock valued at $2,304,000 after acquiring an additional 87,544 shares during the last quarter. Van ECK Associates Corp lifted its stake in shares of Artivion by 65.9% during the 2nd quarter. Van ECK Associates Corp now owns 10,749 shares of the company’s stock worth $242,000 after purchasing an additional 4,269 shares during the period. Finally, Wellington Management Group LLP boosted its holdings in shares of Artivion by 9.0% during the second quarter. Wellington Management Group LLP now owns 1,260,279 shares of the company’s stock worth $28,318,000 after purchasing an additional 103,592 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.